A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Explore this paper's citation graph
Summary
This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agent.
- Type
- review
- Published
- 2021-12-01
- Cited by
- 7
- References
- 168
- Access
- Open access
- OpenAlex
- https://openalex.org/W4200327070
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:245303501
Keywords
Multiple myeloma, Bortezomib, Mechanism (biology), Chemistry, Pharmacology
References
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- Type 2 Diabetes as a Protein Misfolding Disease
- A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities.
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
- 20S proteasome and its inhibitors: crystallographic knowledge for drug development.
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- Anticancer activities of histone deacetylase inhibitors
- Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
- Endoplasmic reticulum stress in malignancy.
- Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.
- Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
- Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.
- Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates.
- Degrasyn-like Symmetrical Compounds: Possible Therapeutic Agents for Multiple Myeloma (MM-I)
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
- From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
- Regulation of STAT Signaling by Acetylation
- Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases
- Next-generation proteasome inhibitor approved in multiple myeloma
Cited by
- Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
- Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance.
- Design, synthesis, and biological evaluation of some novel naphthoquinone‐glycine/β‐alanine anilide derivatives as noncovalent proteasome inhibitors
- Advances in research on potential inhibitors of multiple myeloma.
- In Silico Exploration of New Inhibitors of Protein Kinases Containing an N-Phenylbenzamide Linker: A Combination of Docking and Molecular Dynamics Modeling, Pharmacophore Modeling and Virtual Screening
- How Temperature Change Affects the Lattice Parameters, Molecular Conformation, and Reaction Cavity in Enantiomeric and Racemic Crystals of Thalidomide.
- Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives.
- Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma
Related papers
- Effect of Bortezomib on serum cystatin-C in multiple myeloma
- Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
- Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
- [Proteasome inhibitors in treatment of multiple myeloma].
- Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma
- Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma
- Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
- Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
- Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation
- [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].